Beyond Air, Inc. Stock News

Beyond Air, Inc. (NASDAQ:XAIR) COO Amir Avniel sold 32,675 shares of the stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $13.72, for a total transaction of $448,301.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Shares of []

Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures

NEW YORK , Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, CODX, PRPO, XAIR, and CEMI. … Full story available on Benzinga.com

Beyond Air, Inc. (NASDAQ:XAIR) Director Ron Bentsur sold 37,464 shares of the businesss stock in a transaction on Wednesday, November 24th. The stock was sold at an average price of $13.53, for a total transaction of $506,887.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through []

Beyond Air, Inc. (NASDAQ:XAIR) Director Ron Bentsur sold 37,464 shares of the firms stock in a transaction dated Wednesday, November 24th. The shares were sold at an average price of $13.53, for a total transaction of $506,887.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed []

Beyond Air, Inc. (NASDAQ:XAIR) Director Robert Carey bought 12,000 shares of Beyond Air stock in a transaction dated Friday, November 19th. The stock was purchased at an average cost of $14.10 per share, with a total value of $169,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

Vanguard Group Inc. grew its stake in shares of Beyond Air, Inc. (NASDAQ:XAIR) by 3.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 751,247 shares of the companys stock after acquiring an additional 27,320 shares during the quarter. Vanguard Group Inc.s holdings in Beyond Air were worth $4,868,000 at the end of []

Shares of Beyond Air, Inc. (NASDAQ:XAIR) have been assigned a consensus rating of Buy from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target []

Beyond Air (NASDAQ:XAIR) had its price objective increased by Roth Capital from $11.00 to $15.00 in a research note released on Monday morning, The Fly reports. They currently have a buy rating on the stock. Several other research firms have also weighed in on XAIR. Zacks Investment Research upgraded shares of Beyond Air from a []

Beyond Air® retains 80% equity ownership of Beyond Cancer™, reaching the maximum allowable allotment of committed capital Beyond Air® retains 80% equity ownership of Beyond Cancer™, reaching the